UNSPSC 51362504: Etodroxizine

This classification denotes a sedative and hypnotic with the molecular formula C23H31ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CI1S3XAK7O, chemically known as 3,6-dioxaoctanol, 8-(4-(4-chlorophenylphenylmethyl)piperazinyl)- but generally known as etodroxizine, which bears US NIH Compound Identifier 63345. European Medicines Agency schedules Etodroxizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07317MIG.

UNSPSC 51362504 Etodroxizine, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The recent opportunities record naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — none of which concern etodroxizine specifically. The code shows little relevant recent activity for the named substance.

Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; the Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026. State and local procurement under this code tag appears concentrated in Florida, Texas, and Minnesota, but the substance-level misalignment suggests the tagging reflects a cataloging error rather than a reliable signal for etodroxizine-focused business development.